Bremelanotide for libido and ED: what the trials actually found

What did @bane_syndicate actually say?

Honestly, this is a tough one to fact-check in the traditional sense. The transcript provided is garbled to the point of being incoherent, full of nonsensical phrases like references to "the city of El Cagolo" and making someone "a good friend." This reads like a failed auto-transcription of a non-English video, which tracks given the Russian-language caption. So we're working primarily from the written caption, which is where the actual claims live.

The caption promotes bremelanotide as something that "acts on the brain, triggering natural mechanisms of attraction and arousal" and claims it works for both men and women. It also lists low libido, erectile dysfunction, frigidity, and anorgasmia as problems it "solves." The word "solves" is doing a lot of heavy lifting here, and that framing deserves scrutiny.

Does the science back this up?

Partially, but the devil is in the details. Bremelanotide (sold as Vyleesi in the US) is an FDA-approved melanocortin receptor agonist, specifically approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. That part is real. The central nervous system mechanism is also real: it acts on MC3R and MC4R receptors in the brain to influence sexual response.

What the research actually shows is more modest than "solves" implies. The pivotal clinical trials (Kingsberg et al., 2019, Journal of Sexual Medicine) showed statistically significant but clinically modest improvements in desire scores compared to placebo. Women in the trial reported about one additional satisfying sexual event per month. That is not nothing, but it is not a transformation either. For men and erectile dysfunction specifically, the evidence is far thinner. Early phase II data existed, but bremelanotide never received FDA approval for male sexual dysfunction.

What did they get wrong (or right)?

They got the basic mechanism right: bremelanotide does work centrally, not peripherally like PDE5 inhibitors. That distinction is worth making, and credit where it is due.

But calling it a solution for erectile dysfunction in men is a stretch the data does not support. The FDA reviewed this drug specifically for women. Claiming it addresses male ED without that qualifier is misleading. The claim about "frigidity and anorgasmia" is also oversimplified. The approved indication is HSDD, a specific diagnosis with diagnostic criteria, not a general label for any sexual difficulty a woman might experience.

The framing of "natural mechanisms" is a marketing phrase, not a scientific one. Injecting a synthetic peptide to stimulate receptor pathways is not more "natural" than any other pharmacological intervention. That kind of language is designed to reduce perceived risk, which is a problem given that bremelanotide has real side effects: nausea is reported in roughly 40 percent of users (Clayton et al., 2016, Journal of Sexual Medicine), and transient blood pressure increases are documented. None of that gets mentioned in this content.

What should you actually know?

Bremelanotide is a legitimately interesting drug with real FDA-approved uses, which makes misleading content about it more frustrating, not less. If you have been diagnosed with HSDD and are premenopausal, this is a drug worth discussing with a licensed provider who can evaluate whether you are a candidate and explain the side effect profile.

It is not a general libido booster. It is not proven to treat male erectile dysfunction. It is not something to self-administer based on a TikTok caption. The drug requires subcutaneous injection 45 minutes before anticipated sexual activity, it should not be used more than once in 24 hours, and people with cardiovascular conditions face additional risks from the transient hypertensive effect (Simon et al., 2019, Obstetrics and Gynecology).

If you encounter peptide content that promises to "solve" sexual dysfunction without mentioning side effects, dosing complexity, or the difference between approved and off-label use, that is a content creator optimizing for engagement, not your health outcomes.

The regulatory picture matters here

Bremelanotide sits in an interesting regulatory space. The brand Vyleesi is FDA-approved. Compounded versions exist through some telehealth platforms and peptide providers. These are not the same product, and they have not undergone the same scrutiny. Compounded bremelanotide may vary in purity, concentration, and formulation. Anyone offering it should be transparent about whether they are prescribing the approved product or a compounded version, and what that distinction means for safety and efficacy data.